Efficacy and safety of neoadjuvant camrelizumab and apatinib combined with chemotherapy in stage IIIA (N2) NSCLC: a multi-center, single-arm, phase II trial
The synergistic application of chemotherapy with camrelizumab and apatinib showed clinically meaningful anti-tumor activity and manageable safety, with few hematologic toxicities, and might be a promising therapeutic alternative for individuals with resectable stage IIIA (N2) NSCLC.
Authors
- Lihuan Zhu (ORCID: https://orcid.org/0000-0003-4734-9720)
- Wenshu Chen (ORCID: https://orcid.org/0000-0002-8906-5593)
- Yi Zhang (ORCID: https://orcid.org/0009-0002-9025-0654)
- Tianxing Guo (ORCID: https://orcid.org/0000-0002-2006-5157)
- Zhen Huang (ORCID: https://orcid.org/0000-0002-8908-0355)
- Shuxing Chen (ORCID: https://orcid.org/0000-0002-5546-342X)
- Rongzhi Huang (ORCID: https://orcid.org/0000-0003-2773-6635)
- Lilan Zhao (ORCID: https://orcid.org/0000-0001-9862-1785)
- Yangyun Huang
- Liren Guo
- Nan Zhang (ORCID: https://orcid.org/0000-0001-6518-2501)
- Ning Li (ORCID: https://orcid.org/0000-0002-3266-3322)
- Xing Chen (ORCID: https://orcid.org/0000-0002-9087-4232)
- Xiaojie Pan (ORCID: https://orcid.org/0000-0002-8358-8713)
- Guojun Geng
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Xiamen University (CN)
- Zhangzhou Municipal Hospital of Fujian Province (CN)
- Fuzhou Pulmonary Hospital of Fujian (CN)
- Fujian Provincial Hospital (CN)
Publication Details
- Journal
- BMC Medicine
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1186/s12916-025-04416-0
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
- Fujian Medical University